TERT rearrangements only affected high-risk tumors and occurred in a mutually exclusive manner with the amplification of MYCN and deletion of ATRX. In an extended case series (n = 217), TERT rearrangements were detected in 28 cases (13%), of which 27 (24%) were high-risk and Stage 4 NB patients with a poor clinical outcome [9]. This evidence concerns the gene ATRX and neuroblastoma.